Hepatocellular carcinoma after a sustained virological response by direct‐acting antivirals harbors TP53 inactivation
Authors:
- Taisuke ImamuraTITaisuke Imamura
- Yukiyasu OkamuraYOYukiyasu Okamura
- Keiichi OhshimaKOKeiichi Ohshima
- Teiichi SugiuraTSTeiichi Sugiura
- Takaaki ItoTITakaaki Ito
- Yusuke YamamotoYYYusuke Yamamoto
- Ryo AshidaRARyo Ashida
- Katsuhisa OhgiKOKatsuhisa Ohgi
- Shimpei OtsukaSOShimpei Otsuka
- Takeshi NagashimaTNTakeshi Nagashima
Open Access
- 17 February 2022
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 11 (8) , 1769-1786
Abstract
Introduction The genomic characteristics of hepatocellular carcinoma (HCC) after a sustained virological response (SVR) and its differences according to whether an SVR was achieved by treatment with direct-acting antivirals (DAA) or interferon (IFN) are still not fully understood. Methods Sixty-nine surgically resected HCCs from patients with hepatitis C virus infection were analyzed by gene expression profiling and whole-exome sequencing. Results Among the 69 HCC patients, 34 HCCs in which an SVR was not achieved at the time of surgery were classified as HCV-positive, and 35 HCCs in which an SVR was achieved at the time of surgery were classified as HCV-SVR. According to the HCV treatment, 35 HCV-SVR HCCs were classified into two groups: eight tumors with DAA (HCV-SVR-DAA) and 24 tumors with interferon (HCV-SVR-IFN). The frequency of samples with ARID2 mutations was significantly lower in HCV-SVR than in HCV-positive tumors (p = 0.048). In contrast, the frequency of samples with PREX2 mutations was significantly higher in HCV-SVR samples than in HCV-positive samples (p = 0.048). Among the patients with HCV-SVR, the frequency of samples with TP53 mutations was significantly higher in HCV-SVR-DAA tumors than in HCV-SVR-IFN tumors (p = 0.030). TP53 inactivation scores in HCV-SVR-DAA tumors were found to be significantly enhanced in comparison to HCV-SVR-IFN tumors (p = 0.022). In addition, chromosomal instability and PI3K/AKT/mTOR pathway signatures were enhanced in HCV-SVR-DAA tumors. HCV-SVR-DAA was significantly associated with portal vein invasion (p = 0.003) in comparison to HCV-SVR-IFN. Conclusion Our dataset potentially serves as a fundamental resource for the genomic characteristics of HCV-SVR-DAA tumors. Our comprehensive genetic profiling by WES revealed significant differences in the mutation rate of several driver genes between HCV-positive tumors and HCV-SVR tumors. Furthermore, it was revealed that the frequency of samples with mutations in TP53 was significantly higher in HCV-SVR-DAA tumors than in HCV-SVR-IFN tumors.Keywords
This publication has 67 references indexed in Scilit:
- Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinomaNature Genetics, 2012
- Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancerBreast Cancer Research, 2010
- Activation of the PI3K Pathway in Cancer Through Inhibition of PTEN by Exchange Factor P-REX2aScience, 2009
- Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP‐9Hepatology Research, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- The type 2C phosphatase Wip1: An oncogenic regulator of tumor suppressor and DNA damage response pathwaysCancer and Metastasis Reviews, 2008
- A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancersNature Genetics, 2006
- PI3K/Akt signaling regulates p27kip1 expression via Skp2 in PC3 and DU145 prostate cancer cells, but is not a major factor in p27kip1 regulation in LNCaP and PC346 cellsThe Prostate, 2006
- Truncating mutations of hSNF5/INI1 in aggressive paediatric cancerNature, 1998
- Genomic instability and the role of p53 mutations in cancer cellsCurrent Opinion in Oncology, 1995